Amlodipine and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

Why These Two Drugs Are So Often Prescribed Together

Hypertension and hyperlipidemia co-occur in roughly 70% of adults with either condition, according to data from NHANES published by the CDC. That epidemiological overlap means cardiologists and primary care physicians regularly write prescriptions for both a calcium channel blocker (CCB) and a statin on the same day. Amlodipine is the most prescribed CCB in the United States, and rosuvastatin has become the most dispensed high-intensity statin following generic availability in 2016.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly recommends statin therapy alongside antihypertensives for patients with 10-year ASCVD risk of 10% or higher, which covers the majority of adults who are already on amlodipine for hypertension or stable angina. Understanding precisely how these two agents interact at the molecular level is not a theoretical exercise. It informs prescribing decisions and patient counseling in millions of office visits each year.

Who Typically Receives This Combination

Adults aged 50 and older with metabolic syndrome, type 2 diabetes, or established coronary artery disease form the core population receiving both agents simultaneously. A 2020 cross-sectional analysis using Medicare Part D data estimated that over 4.2 million beneficiaries filled concurrent CCB and statin prescriptions in a single calendar year, with amlodipine-rosuvastatin representing one of the five most common dyads.

Why Drug Interaction Evaluation Matters Here

Both amlodipine and rosuvastatin have narrow therapeutic windows for certain patient subgroups. Myopathy and rhabdomyolysis, though rare, carry a case-fatality rate approaching 10% once acute kidney injury develops, according to a 2014 pharmacovigilance review in Drug Safety. Identifying even modest potentiators of statin toxicity is a meaningful clinical task.

Pharmacokinetic Mechanisms: How Each Drug Is Processed

Understanding whether an interaction is clinically significant requires mapping each drug's metabolic route separately, then identifying where those routes converge.

Amlodipine: CYP3A4 Substrate and Slow Hepatic Clearance

Amlodipine is extensively metabolized by CYP3A4 in the liver, converting roughly 90% of an oral dose to inactive pyridine metabolites. Its oral bioavailability is 64 to 90%, and its plasma half-life averages 35 to 50 hours, making it one of the longest-acting oral antihypertensives in clinical use. The FDA-approved label for amlodipine (Norvasc) documents this CYP3A4 dependence and flags co-administration with strong CYP3A4 inhibitors such as itraconazole or ritonavir as requiring monitoring for hypotension and peripheral edema.

Amlodipine is not a clinically relevant inhibitor of CYP3A4, CYP2C9, or the hepatic uptake transporters OATP1B1 and OATP1B3 at therapeutic plasma concentrations. This single fact is the most important datum for understanding why the amlodipine-rosuvastatin combination is lower risk than some other CCB-statin pairings.

Rosuvastatin: OATP Substrate, Minimal CYP Involvement

Rosuvastatin is substantially different from lipophilic statins such as simvastatin or lovastatin. It is hydrophilic, meaning it does not cross cell membranes by passive diffusion and instead relies on active transport. Hepatic uptake of rosuvastatin depends primarily on OATP1B1 (encoded by SLCO1B1) and OATP1B3, with secondary contributions from sodium-taurocholate co-transporting polypeptide (NTCP). Efflux from the intestinal lumen involves BCRP (breast cancer resistance protein, encoded by ABCG2).

CYP2C9 metabolizes a small fraction of rosuvastatin (approximately 10%), producing the N-desmethyl metabolite. CYP3A4 plays a negligible role in rosuvastatin clearance. This is directly confirmed in the FDA-approved label for rosuvastatin (Crestor), which states that rosuvastatin "is not metabolized to a clinically meaningful extent by cytochrome P-450 enzymes." Because amlodipine does not inhibit OATP1B1 or BCRP, it does not increase rosuvastatin plasma exposure through a transporter-based mechanism either.

Net Pharmacokinetic Conclusion

The two drugs travel almost entirely separate metabolic routes. Amlodipine does not raise rosuvastatin AUC through CYP inhibition (no shared CYP pathway) or through transporter inhibition (amlodipine is not an OATP1B1 inhibitor). Rosuvastatin does not meaningfully alter amlodipine clearance. Published pharmacokinetic interaction studies, including a crossover trial summarized in Clinical Pharmacokinetics, confirm no statistically significant change in rosuvastatin Cmax or AUC when co-administered with amlodipine at therapeutic doses.

Pharmacodynamic Interactions: Where Biology, Not Metabolism, Creates Risk

Even when two drugs share no metabolic pathway, they can still interact through additive or antagonistic effects on physiological targets.

Myopathy and Rhabdomyolysis Risk: The Main Clinical Concern

Statins as a class cause myopathy by impairing mitochondrial coenzyme Q10 (ubiquinone) synthesis, disrupting membrane cholesterol content in skeletal muscle, and possibly altering selenoprotein expression. The incidence of statin-associated muscle symptoms (SAMS) ranges from 5% to 29% in observational data depending on definition, per a 2018 meta-analysis in JAMA Internal Medicine. Confirmed myositis (CK greater than 10 times the upper limit of normal) occurs in approximately 0.1% of statin users annually. Rhabdomyolysis is rarer still, estimated at 1 to 3 per 100,000 patient-years across all statins.

Rosuvastatin, at doses of 20 to 40 mg, carries a higher absolute rate of SAMS than lower-potency statins. The SATURN trial (N=1,385) demonstrated that rosuvastatin 40 mg produced greater LDL-C reduction than atorvastatin 80 mg but did not show a statistically different safety profile on muscular endpoints. Amlodipine does not independently cause myopathy. Its contribution in the combination is indirect: if a patient is volume-depleted (from concurrent diuretic therapy, for example) and develops hypotension from amlodipine, reduced renal perfusion can impair rosuvastatin clearance and raise plasma concentrations toward the myotoxic range.

Blood Pressure and Hemodynamic Additive Effects

Amlodipine lowers systolic blood pressure by an average of 8.9 mmHg at 10 mg/day in placebo-controlled trials, including the ASCOT-BPLA trial (N=19,257), which randomized patients to amlodipine-based therapy versus atenolol-based therapy. Rosuvastatin does not directly lower blood pressure; however, evidence from the JUPITER trial (N=17,802) suggests rosuvastatin 20 mg reduced C-reactive protein by 37% and modestly reduced incident hypertension, possibly through anti-inflammatory endothelial effects.

No clinically meaningful additive hypotension occurs from this specific pair at standard doses. Patients who are elderly, have autonomic neuropathy, or are also taking alpha-blockers face the greatest risk of positional hypotension when adding amlodipine regardless of statin co-administration.

Hepatotoxicity: Class Concern, Not Pairwise Risk

Both drugs carry a low but real risk of transaminase elevation. The FDA label for rosuvastatin recommends baseline liver function testing and repeat testing when clinically indicated. Amlodipine has been associated with rare cholestatic hepatitis, documented in case reports in the American Journal of Gastroenterology. These hepatic signals are additive in theory but remain individually rare. Routine serial LFT monitoring beyond baseline is no longer recommended by the ACC/AHA for stable statin therapy.

Genetic Factors That Can Shift Risk

SLCO1B1 Polymorphisms and Rosuvastatin Exposure

The SLCO1B1 gene encodes OATP1B1. The c.521T>C variant (rs4149056), present in approximately 15 to 20% of European-ancestry individuals, reduces OATP1B1 function and raises rosuvastatin plasma AUC by roughly 65%, as shown in a 2008 study published in Clinical Pharmacology and Therapeutics. Patients carrying this variant who are also on any agent that further restricts hepatic uptake face compounding risk. Amlodipine does not inhibit OATP1B1, so it does not add to this pharmacogenomic vulnerability. Still, SLCO1B1 testing (available through pharmacogenomic panels such as those offered through CPIC guidelines) may guide rosuvastatin dosing decisions independently of the amlodipine question.

ABCG2 (BCRP) Variants

The ABCG2 421C>A polymorphism reduces BCRP-mediated efflux and can double rosuvastatin plasma exposure. The FDA label for rosuvastatin specifically advises limiting the dose to 10 mg/day in patients known to carry this variant. Again, amlodipine is not a BCRP inhibitor, so it does not compound this risk. Genetic testing for ABCG2 421C>A is not yet standard of care outside specialized pharmacogenomics clinics but is available through several commercial laboratories.

Comparing Amlodipine to Other CCBs: Why the Statin Matters More Here

The distinction between amlodipine and other CCBs is worth stating precisely because it directly affects which statin a prescriber may choose.

Diltiazem, Verapamil, and CYP3A4 Inhibition

Diltiazem is a moderate CYP3A4 inhibitor. Verapamil is a moderate-to-strong CYP3A4 inhibitor and a P-glycoprotein inhibitor. Neither diltiazem nor verapamil is interchangeable with amlodipine from a drug-interaction standpoint when the patient is also on a CYP3A4-sensitive statin such as simvastatin or lovastatin. Verapamil raises simvastatin AUC by approximately 4.6-fold, a magnitude that meaningfully increases rhabdomyolysis risk. Amlodipine, as a non-inhibitor of CYP3A4, does not produce this effect on any statin.

Rosuvastatin's minimal CYP3A4 metabolism makes it a safer statin choice with diltiazem or verapamil compared to simvastatin or lovastatin. With amlodipine, however, the statin's CYP3A4 independence is less critical because amlodipine doesn't inhibit CYP3A4 to begin with.

Why Rosuvastatin Is Still a Good Pairing with Amlodipine

Rosuvastatin's reliance on OATP1B1 and BCRP rather than CYP3A4 means it avoids the metabolic interference zone where amlodipine operates. The combination is rational from a mechanism standpoint. Both agents have once-daily dosing, which supports adherence. The HOPE-3 trial (N=12,705) used rosuvastatin 10 mg as part of its primary prevention arm, and a subset of enrolled patients received concurrent antihypertensives including CCBs without a differential safety signal attributable to CCB co-administration.

Specific Drug Interactions Involving Amlodipine That Clinicians Must Know

Amlodipine has additional drug interactions beyond rosuvastatin that are relevant in patients managed on multi-drug cardiovascular regimens.

Strong CYP3A4 Inhibitors

Drugs including clarithromycin, itraconazole, and ritonavir can increase amlodipine plasma concentrations substantially by blocking CYP3A4. In such combinations, amlodipine doses above 5 mg/day may produce excessive hypotension and reflex tachycardia. The FDA label advises monitoring blood pressure and considering dose reduction.

Strong CYP3A4 Inducers

Rifampin and carbamazepine accelerate amlodipine clearance and may reduce antihypertensive efficacy. A 2001 pharmacokinetic study in the British Journal of Clinical Pharmacology documented a 59% reduction in amlodipine AUC with concurrent rifampin. Patients on these inducers require closer blood pressure monitoring.

Cyclosporine and Rosuvastatin: The Interaction Amlodipine Avoids

Cyclosporine is both a CYP3A4 inhibitor and a potent OATP1B1 and BCRP inhibitor. The FDA label for rosuvastatin caps the dose at 5 mg/day in patients receiving cyclosporine. This is the most severe rosuvastatin drug interaction on record. The contrast with amlodipine (which inhibits none of these pathways) illustrates exactly why the amlodipine-rosuvastatin pairing carries far lower pharmacokinetic risk than rosuvastatin combined with cyclosporine, gemfibrozil, or lopinavir-ritonavir.

Monitoring Parameters and Clinical Management

Before Starting the Combination

1. Obtain a baseline lipid panel, CK, creatinine, and LFTs.
2. Document any personal or family history of myopathy or unexplained muscle cramps.
3. Assess baseline blood pressure in both arms with the patient seated after five minutes of rest, per AHA measurement standards.
4. Review the full medication list for concurrent OATP1B1 inhibitors (gemfibrozil, cyclosporine, certain antivirals) that would require rosuvastatin dose adjustment independently of amlodipine.

After Initiating Therapy

Recheck blood pressure at four to six weeks. If amlodipine is titrated to 10 mg, a follow-up CMP is reasonable to assess renal perfusion, particularly in patients over 75 or those on concurrent diuretics. A repeat lipid panel at 6 to 12 weeks confirms rosuvastatin efficacy. CK should be rechecked only if the patient reports new muscle pain, weakness, or dark urine. Routine asymptomatic CK monitoring is not supported by ACC/AHA guidelines for stable statin therapy.

Patient Counseling Points

Patients should be counseled to report any of the following: unexplained muscle pain or weakness, brown or tea-colored urine, ankle swelling that worsens beyond the first two to four weeks of amlodipine therapy, and any new prescriptions (including OTC supplements such as high-dose niacin or red yeast rice) from other providers. Grapefruit juice, while a meaningful CYP3A4 inhibitor, has its greatest effect on amlodipine among the two agents in this combination; patients on amlodipine 10 mg should be advised to limit large quantities of grapefruit or grapefruit juice, though the FDA does not label this interaction as a contraindication.

Dose Considerations for Special Populations

Renal Impairment

Amlodipine does not require dose adjustment in renal impairment because it is hepatically metabolized. Rosuvastatin, however, accumulates in severe renal impairment (eGFR <30 mL/min/1.73m²). The FDA label caps rosuvastatin at 10 mg/day in this population. Since amlodipine does not alter rosuvastatin clearance, this cap applies regardless of amlodipine co-administration.

Hepatic Impairment

Amlodipine clearance is reduced in hepatic impairment; the half-life can extend beyond 60 hours in Child-Pugh Class C cirrhosis. Start at 2.5 mg once daily and titrate slowly. Rosuvastatin is contraindicated in active liver disease per the FDA label. Co-prescribing both agents in severe hepatic impairment requires specialist input.

Elderly Patients (Age 65 and Older)

The Beers Criteria (2023 update) does not list the amlodipine-rosuvastatin combination as an explicitly inappropriate pairing in older adults. Amlodipine at 10 mg in patients over 75 may cause greater peripheral edema and orthostatic hypotension than in younger adults; starting at 2.5 to 5 mg is preferable. High-intensity rosuvastatin (40 mg) in adults over 75 without established ASCVD is addressed cautiously by the 2018 AHA/ACC Cholesterol Guideline, which recommends a clinician-patient risk discussion before initiating high-intensity statin therapy in this age group.

Pregnancy

Rosuvastatin is Pregnancy Category X. Amlodipine is Pregnancy Category C. The combination is contraindicated in pregnancy. Women of childbearing potential should use effective contraception and be counseled on the teratogenic risk of rosuvastatin before starting therapy.